SCHEMBL4367775

SCHEMBL4367775

CCn1nc(C)cc1C(=O)NC(=O)N(S)c1cccc(OCCc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
SMYD3 Q9H7B4 2/20 0.38
MAPT P10636 1/20 0.38
KDR P35968 1/20 0.38
FGFR1 P11362 1/20 0.36
HPGD P15428 1/20 0.36
PTGES O14684 2/20 0.36
ALOX5 P09917 2/20 0.36
PPARG P37231 2/20 0.36
NR1H4 Q96RI1 1/20 0.36
SLC2A1 P11166 1/20 0.36
FFAR1 O14842 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4366066 0.80 NPC1 (0.43) MTNR1AMTNR1BMAPTHPGDSIRT2
SCHEMBL4367771 0.80 ALDH1A1 (0.53) MAPTKDRFGFR1HPGDNR1H4
SCHEMBL4373602 0.78 CYP1A2 (0.46) MTNR1AMTNR1BHPGDNR1H4SLC2A1
SCHEMBL4370528 0.77 TSHR (0.48) MTNR1AMTNR1BMAPTHPGDPPARG
SCHEMBL4543064 0.74 SIRT2 (0.47) MTNR1AMTNR1BNR1H4SLC2A1SIRT2
SCHEMBL4365507 0.73 HPGD (0.53) MTNR1AMTNR1BMAPTHPGDSIRT2
SCHEMBL4375354 0.73 MAPK14 (0.49) PPARGNR1H4SLC2A1FFAR1MEN1
SCHEMBL3979441 0.70 MTNR1A (0.60) MTNR1AMTNR1BHPGDPPARGMEN1
SCHEMBL4999591 0.68 MTNR1A (0.55) MTNR1AMTNR1BPPARGNR1H4FFAR1
SCHEMBL4982213 0.68 MTNR1A (0.55) MTNR1AMTNR1BPPARGNR1H4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
EP-1562895-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004046095-A1 SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT MTNR1A 1818/4885MTNR1B 2248/4885SMYD3 2042/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 MTNR1A 1328/4885MTNR1B 1874/4885SMYD3 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.